Clinical Trial: Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study

Brief Summary:

RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer, patients with colorectal polyps and from patients without polyps may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at biomarkers in blood and tissue samples from patients with colorectal cancer or colorectal polyps and from patients without polyps (healthy volunteers).


Detailed Summary:

OBJECTIVES:

Primary

  • Perform metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling using blood and tissue samples from patients with colorectal cancer (CRC) or colorectal adenomatous polyps and from patients without polyps.
  • Create an OMIC profile to predict the risk of CRC based on differences observed between patients with CRC, patients with colorectal adenomatous polyps, and patients without polyps.

Secondary

  • Create an OMIC profile to predict response and toxicity to specific chemotherapies, biological therapies, and radiotherapy for CRC.
  • Utilize a novel knowledge discovery tool (BioMap) based on literature mining and, in the future, utilize the results of the OMIC analyses to identify interactive molecular pathways that underlie the development and progression of CRC.

OUTLINE: Patients with locally advanced or metastatic colorectal cancer are stratified according to treatment (first-line chemotherapy with fluorouracil [5-FU]/oxaliplatin or 5-FU/irinotecan vs second- or third-line chemotherapy with irinotecan only vs biological therapy with bevacizumab vs biological therapy with cetuximab vs radiotherapy).

Blood and tissue samples are collected periodically for laboratory studies. Samples are analyzed for metabolomics by nuclear magnetic resonance, gas chromatography, liquid chromatography, and mass spectrometry; lipidomics, proteomics, and glycoproteomics by liquid chromatography and mass spectrometry; and genomics (single nucleotide polymorphism biomark
Sponsor: Indiana University

Current Primary Outcome:

  • Metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling [ Time Frame: End of Study ]
  • Creation of an OMIC profile to predict the risk of colorectal cancer (CRC) [ Time Frame: End of Study ]


Original Primary Outcome:

  • Metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling
  • Creation of an OMIC profile to predict the risk of colorectal cancer (CRC)


Current Secondary Outcome:

  • Creation of an OMIC profile to predict response and toxicity to specific therapies for CRC [ Time Frame: End of Study ]
  • Identification of interactive molecular pathways that underlie the development and progression of CRC [ Time Frame: End of Study ]


Original Secondary Outcome:

  • Creation of an OMIC profile to predict response and toxicity to specific therapies for CRC
  • Identification of interactive molecular pathways that underlie the development and progression of CRC


Information By: Indiana University

Dates:
Date Received: May 9, 2009
Date Started: January 2009
Date Completion:
Last Updated: September 17, 2014
Last Verified: September 2014